Aurobindo Pharma has announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Glycerol Phenylbutyrate Oral Liquid, which contains 1.1 grams per mL. This product is bioequivalent and therapeutically equivalent to the reference listed drug, Ravicti Oral Liquid, developed by Horizon Therapeutics U.S. Holding LLC. The approved Glycerol Phenylbutyrate is indicated for patients with urea cycle disorders (UCDs) who cannot be managed solely through dietary protein restriction or amino acid supplementation. The product is expected to enter a market valued at approximately $50.2 million for the twelve months ending February 2026, according to IQVIA MAT. With this approval, Aurobindo Pharma now holds a total of 579 Abbreviated New Drug Application (ANDA) approvals from the USFDA, which includes 556 final approvals and 23 tentative approvals. The product will be manufactured at the company's Unit-III and is set for immediate launch.